treatment News

BERLIN — Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R) antibody blinatumomab (MT103) at the 14th Congress of the European Hematology...
HOUSTON – Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor,...
BALTIMORE — The 2009 monsoon season will soon arrive in the Asian territories and culicine mosquito populations are expected to increase. “These mosquitoes may carry the virus that causes Japanese Encephalitis (JE), which kills 10-15,000 people each year,” warned Fran Lessans, CEO of Passport Health, the largest provider of travel...
Atlanta, Ga. – Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantly higher levels of treatment satisfaction after three infusions with TYSABRI® (natalizumab) when compared to multiple sclerosis (MS) therapies used previously. The...
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects. Bethlem Myopathy and Ullrich Congenital Muscular...
ROCKVILLE, Md. – NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 portion of a study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in patients with newly diagnosed, non-severe lymphopenic high grade glioma (HGG), following standard...
HERZLIYA, Israel – NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming at slowing or halting the disease progression, announces the successful completion of its first Phase IIa study. The study, NST002, aimed at establishing various safety...